Nasdaq Denies Actelis Networks' Appeal, Shares to Be Suspended and Transition to OTC Market
ASNS is trading near its 52-week low of $0.1 (8.0% above the low) on light trading volume (0.3× avg).
Summary
Actelis Networks' appeal to remain on Nasdaq was denied, leading to the suspension of its common stock trading on April 10, 2026, and a transition to the OTC market.
Key Events · Corporate Governance and Compliance · ASNS
-
Nasdaq Delisting Confirmed
Nasdaq denied the company's appeal for continued listing, confirming that trading of its common stock will be suspended at the open of business on April 10, 2026.
-
Transition to OTC Market
The company's common stock will transition from Nasdaq to the OTC Markets Group, Inc., with plans to apply for trading on the OTCQB Venture Market.
-
Prior Reverse Stock Split
The delisting follows the company's failure to maintain a minimum bid price of $1.00, despite having effected a 1-for-10 reverse stock split on November 18, 2025.
Analysis · ASNS · Manufacturing
The denial of the appeal and subsequent delisting from Nasdaq to the OTC market represents a significant downgrade in the company's public market standing. While management states operations will not be impacted and they will explore relisting options, the move typically results in reduced liquidity, lower investor visibility, and can deter institutional investment. The prior reverse stock split failing to prevent delisting highlights persistent challenges in meeting listing requirements.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ASNS was trading at $0.11 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $9M. The 52-week trading range was $0.10 to $8.60. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.